LGND241220P175000
- 0.00
- 0.000.00%
Ligand Pharmaceuticals Newsroom
Ligand Pharmaceuticals Is Maintained at Overweight by Barclays
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $160
Ligand Pharmaceuticals Is Maintained at Outperform by RBC Capital
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Oppenheimer Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $151
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $143
Ligand Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $157
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $141
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $150
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $140
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $135 to $150
Ligand Pharmaceuticals Analyst Ratings
Ligand Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $150
H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $157
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating